ALK and non-small cell lung carcinoma: After that, the study published by Weickhardt et al. in 2012 [27] was a retrospective analysis of patients with metastatic NSCLC harboring ALK+ and EGFR-MT mutations and with oligoprogressive disease (i.e., progression within the central nervous system and/or limited systemic sites) while receiving crizotinib or erlotinib.